A Study to Evaluate the Drug-drug Interaction Potential of BMS-986196 in Healthy Participants

Completed · Phase 1

Conditions studied: Healthy Volunteers

In brief

This study is designed to assess the effect of BMS-986196 on the drug levels of caffeine, montelukast, flurbiprofen, omeprazole, midazolam, digoxin, and pravastatin in healthy participants.

Key facts

Study ID

NCT05852769

Run by

Bristol-Myers Squibb

People needed

18

Starts

2023-05-31

Expected to finish

2023-08-24

Last updated by the study team

2023-09-26

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy male and female participants as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations.
• Body mass index of 18.0 to 33.0 kilogram per meter squared (kg/m\^2), inclusive, and body weight ≥50.0 kg.

You may not qualify if…

• History of rhabdomyolysis.
• History of peptic ulcer disease or significant GI bleeding.
• History of malignancy in the 5 years prior to screening (except fully excised basal cell carcinoma).

Where it is running

• ICON plc — Millcreek, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.